- Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
- Alvotech birtir uppgjör fyrir fyrsta ársfjórðung 2024 og kynnir nýjustu áfanga í rekstri félagsins
- Alvotech gengur til samstarfs við Dr. Reddy‘s um markaðssetningu AVT03, fyrirhugaðrar hliðstæðu við Prolia og Xgeva, í Bandaríkjunum og Evrópu
- Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
- Alvotech og Teva Pharmaceuticals hefja sölu á líftæknilyfjahliðstæðunni Simlandi í Bandaríkjunum
- Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
- Alvotech S.A. Annual General Meeting to be held June 7, 2024
- Aðalfundur Alvotech S.A. boðaður 7. júní 2024
- Alvotech kynnir uppgjör fyrsta ársfjórðungs 2024 22. maí nk. kl. 12 að íslenskum tíma
- Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
More ▼
Key statistics
On Tuesday, Alvotech SA (ALVO:NMQ) closed at 13.94, -22.56% below its 52-week high of 18.00, set on Feb 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.56 |
---|---|
High | 13.94 |
Low | 13.56 |
Bid | 14.25 |
Offer | 15.25 |
Previous close | 13.50 |
Average volume | 85.20k |
---|---|
Shares outstanding | 266.82m |
Free float | 72.59m |
P/E (TTM) | -- |
Market cap | 3.72bn USD |
EPS (TTM) | -2.40 USD |
Data delayed at least 15 minutes, as of May 21 2024 21:00 BST.
More ▼